Agile Therapeutics Inc (NASDAQ: AGRX) is running for the top yet again today, gaining 22.75% thus far. The gains started on Wednesday of last week after an FDA Advisory Committee surprised the investing community with a vote in the company’s favor. Now, the big question is, “How high can this thing go?”
AdCom Shocker Sends AGRX Skyward
Before we get into just how high Agile Therapeutics may fly, it’s important that you understand the full story. Recently, the company released its financial results. Importantly, no one was paying attention to finances.
Instead, there was a big statement that caught the investing community off guard. In the release, the company said that the FDA expressed numerous concerns with regard to the approvability of Twirla. The FDA cited issues with the balance between efficacy and risk among other concerns.
When the news broke, AGRX tumbled. This was a big hit. After all, the company is little to nothing if it doesn’t have Twirla. Sure, it has multiple candidates, but they are mostly Twirla or Twirla-related combination therapies. So, you could imagine the upset that investors were feeling that day.
However, on Wednesday of last week, yet another shocker came. This time, the news was good.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
Click below to continue reading!